Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
NCT00529451
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1613
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Interventions
DRUG:
Aliskiren
DRUG:
Ramipril
Sponsor
Novartis